Hormonal evaluation in schizophrenic patients treated with neuroleptics

Neuroendocrinology Letters

Volumn 20, Issue 3-4, 1999, Pages 199-204

  Melkersson, Kristina ^a   Hulting, Anna Lena ^b   Hall, Kerstin ^b  

^a Löwenströmska Hospital   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Growth hormone (GH); Insulin like growth factor I (IGF I); Neuroleptics; Prolactin (PRL); Side effects

Indexed keywords

GONADOTROPIN; GROWTH HORMONE; NEUROLEPTIC AGENT; PROLACTIN; SOMATOMEDIN; TESTOSTERONE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; MALE; MENSTRUATION DISORDER; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; TESTOSTERONE BLOOD LEVEL;

EID: 0032760007     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Meltzer HY, Sachar EJ, Frantz AG. Dopamine antagonism by thioridazine in schizophrenia. Biol Psychiatry 1975; 10:53-7.
2. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33:279-86.
3. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978; 35:108-16.
4. De Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976; 5:273-82.
5. Naber D, Fischer H, Ackenheil M. Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 1979; 3:59-65.
6. Csernansky JG, Kaplan J, Holman CA, Hollister LE. Serum neuroleptic activity, prolactin and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology 1983; 81:115-8.
7. Tripodianakis J, Markianos M, Garelis E. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin. Biol Psychiatry 1983; 18:337-45.
8. Björndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol and serum prolactin. Psychopharmacology 1980; 67:17-23.
9. Lal S. Growth hormone and schizophrenia. In: Meltzer HY, editor. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. p. 809-18.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R), 3 edn, revised. Washington DC: American Psychiatric Press; 1987.
11. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: Improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991; 124:620-9.
12. Hilding A, Hall K, Wivall-Helleryd I-L, Sääf M, Melin A-L, Thorén M. Serum levels of insulin-like growth factor I (IGF-I) in 152 patients with growth hormone (GH) deficiency aged 19-82 years in relation to healthy subjects. J Clin Endocrinol Metab 1999; 84:2013-9.
13. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976; 33:858-61.
14. Bang P, Hall K. IGFs as endocrine and paracrine hormones. In: Schofield P, editor. Insulin-like growth factors: structure and biological function. New York: Oxford University Press; 1992. p. 151-77.
15. Lilford VA, Lilford RJ, Dacie JE, Rees LA, Browne PD, Chard T. Long-term phenothiazine treatment does not cause pituitary tumours. Brit J Psychiatry 1984; 144:421-4.
16. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19:603-6.
17. Sarkar DK, Gottschall PE, Meites J. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology 1984; 115:1269-74.
18. Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985; 33:800-7.
19. Heidvall K, Hulting A-L. Rapid progression of a growth hormone producing tumour during dopamine agonist treatment. Brit Med J 1987; 294:546-7.
20. Hulting A-L, Hall K, Werner S. Somatomedin A increments are diminished in acromegaly with concomitant hyperprolactinemia. Acta Endocrinol 1984; 106:305-10.
21. Hulting A-L, Grenbäck E, Heidvall K. Prolaktinproducerande tumörer hos barn - en differentialdiagnos till craniopharyngeom. Två fallbeskrivningar. [(Prolactin-producing tumours in children - a differential diagnosis of craniopharyngeoma. Two case reports.) (In Swedish)]. Sandoz tidskrift 1987; 19:36-40.